Cargando…

HER2‐positive breast cancer brain metastasis: A new and exciting landscape

BACKGROUND: Brain metastases (BrM) incidence is 25% to 50% in women with advanced human epidermal growth factor receptor 2 (HER2)‐positive breast cancer. Radiation and surgery are currently the main local treatment approaches for central nervous system (CNS) metastases. Systemic anti‐HER2 therapy fo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zimmer, Alexandra S., Van Swearingen, Amanda E. D., Anders, Carey K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9124511/ https://www.ncbi.nlm.nih.gov/pubmed/32881421 http://dx.doi.org/10.1002/cnr2.1274

Ejemplares similares

Breast cancer brain metastases: evidence for neuronal-like adaptation in a ‘breast-to-brain’ transition?
por: Van Swearingen, Amanda ED, et al.
Publicado: (2014)

Advances in the management of breast cancer brain metastases
por: Sammons, Sarah, et al.
Publicado: (2021)

Systemic Therapy Type and Timing Effects on Radiation Necrosis Risk in HER2+ Breast Cancer Brain Metastases Patients Treated With Stereotactic Radiosurgery
por: Park, Christine, et al.
Publicado: (2022)

OTHR-10. Diverse survival outcomes of HER2+ Breast Cancer Brain Metastases (BrCBM) presenting with isolated brain relapse compared to those with concurrent extracranial disease
por: Noteware, Laura, et al.
Publicado: (2021)

Immunological Landscape of HER-2 Positive Breast Cancer
por: Moragon, Santiago, et al.
Publicado: (2022)

Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan
por: Alder, Laura, et al.
Publicado: (2023)

The Exciting New Field of HER2-Low Breast Cancer Treatment
por: Eiger, Daniel, et al.
Publicado: (2021)

Appendicitis caused by the metastasis of HER2-positive breast cancer
por: Mori, Ryutaro, et al.
Publicado: (2016)

Liquid biopsy for HER2-positive breast cancer brain metastasis: the role of the cerebrospinal fluid
por: De Mattos-Arruda, Leticia
Publicado: (2017)

Identification of key genes in HER2-positive breast cancer with brain metastasis via bioinformatics methods
por: Yang, Ziguo, et al.
Publicado: (2023)

THE SPATIAL TRANSCRIPTOMIC LANDSCAPE OF BREAST CANCER BRAIN METASTASIS
por: Abdo, Rober, et al.
Publicado: (2023)

Modulation of Mutational Landscape in HER2-Positive Breast Cancer after Neoadjuvant Chemotherapy
por: Omarini, Claudia, et al.
Publicado: (2020)

Trastuzumab uptake and its relation to efficacy in an animal model of HER2-positive breast cancer brain metastasis
por: Lewis Phillips, Gail D., et al.
Publicado: (2017)

Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial
por: Lin, Nancy U., et al.
Publicado: (2020)

Current Landscape of Targeted Therapy in Hormone Receptor-Positive and HER2-Negative Breast Cancer
por: Andrahennadi, Samitha, et al.
Publicado: (2021)

The efficacy and safety of pyrotinib in treating HER2‐positive breast cancer patients with brain metastasis: A multicenter study
por: Gao, Min, et al.
Publicado: (2021)

The Potential Prognostic Marker TyG Index Predicts Time to Brain Metastasis at HER2 Positive Breast Cancer
por: Karadag, Ibrahim, et al.
Publicado: (2023)

HER2-Positive Gastroesophageal Cancers Are Associated with a Higher Risk of Brain Metastasis
por: Tincknell, Gary, et al.
Publicado: (2022)

Complete pathologic response of HER2-positive breast cancer liver metastasis with dual Anti-HER2 antagonism
por: Schoellhammer, Hans F, et al.
Publicado: (2014)

Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER‐targeted therapy in HER2 amplification‐positive and HER2 mutation‐positive amplification‐negative patients
por: Liu, Binliang, et al.
Publicado: (2022)

BSCI-06 COMPREHENSIVE ANALYSIS OF THE IMMUNOGENOMICS OF TRIPLE NEGATIVE BREAST CANCER BRAIN METASTASES FROM LCCC1419
por: Van Swearingen, Amanda, et al.
Publicado: (2022)

Molecular landscape and emerging therapeutic strategies in breast cancer brain metastasis
por: Xiong, Siyi, et al.
Publicado: (2023)

Current Landscape of Targeted Therapies for Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer
por: Ballinger, Tarah J., et al.
Publicado: (2018)

Current and future landscape of targeted therapy in HER2-positive advanced breast cancer: redrawing the lines
por: Simmons, Christine, et al.
Publicado: (2022)

Distribution analysis of epertinib in brain metastasis of HER2-positive breast cancer by imaging mass spectrometry and prospect for antitumor activity
por: Tanaka, Yukari, et al.
Publicado: (2018)

Prophylactic cranial irradiation reduces the incidence of brain metastasis in a mouse model of metastatic, HER2-positive breast cancer
por: Smith, Daniel L., et al.
Publicado: (2021)

Systemic treatment for brain metastasis in HER2- positive advanced breast cancer: what have we learned so far?
por: Batista, Marta Vaz, et al.
Publicado: (2023)

SDPS-10 DISPARITIES IN THE RISK OF CNS METASTASIS AND CLINICAL OUTCOMES IN PATIENTS WITH HER2- MUTATION POSITIVE (HER2+) NON-BREAST VERSUS HER2+ BREAST CANCERS
por: Elghawy, Omar, et al.
Publicado: (2023)

The landscape of d16HER2 splice variant expression across HER2-positive cancers
por: Volpi, Chiara Costanza, et al.
Publicado: (2019)

Histone deacetylase 11 inhibition promotes breast cancer metastasis from lymph nodes
por: Leslie, Patrick L., et al.
Publicado: (2019)

Discordances in ER, PR, and HER2 between primary breast cancer and brain metastasis
por: Jung, Jaehag, et al.
Publicado: (2017)

FABP7 is a key metabolic regulator in HER2+ breast cancer brain metastasis
por: Cordero, Alex, et al.
Publicado: (2019)

Effective Treatment of Solitary Pituitary Metastasis with Panhypopituitarism in HER2-Positive Breast Cancer by Lapatinib
por: Park, Youngmok, et al.
Publicado: (2016)

Follistatin is a metastasis suppressor in a mouse model of HER2-positive breast cancer
por: Seachrist, Darcie D., et al.
Publicado: (2017)

Immune cell profiles of metastatic HER2-positive breast cancer patients according to the sites of metastasis
por: Honkanen, Tiia J., et al.
Publicado: (2021)

34. TARGETED THERAPY FOR HER2-POSITIVE BREAST CANCER BRAIN METASTASES: A SYSTEMATIC REVIEW AND META-ANALYSIS
por: Erickson, Anders, et al.
Publicado: (2020)

New Agents for the Management of Advanced HER2-Positive Breast Cancer
por: Royce, Melanie, et al.
Publicado: (2016)

Treatment Landscape for Patients with HER2-Positive Metastatic Breast Cancer: A Review on Emerging Treatment Options
por: Gampenrieder, Simon Peter, et al.
Publicado: (2020)

Prognostic factors of brain metastasis and survival among HER2-positive metastatic breast cancer patients: a systematic literature review
por: Hackshaw, Michelle D., et al.
Publicado: (2021)

Risk Factors of Brain Metastasis and Prognosis in HER2-Positive Breast Cancer: A Single-Institution Retrospective Analysis from China
por: Cai, Shuang-Long, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_tqk8im6254eg275usiaumimnnl